4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds

Patent metadata

Field	Value
Publication number	US-10722504-B2
Application number	US-201916559928-A
Country	US
Kind code	B2
Filing date	Sep 4, 2019
Priority date	Nov 14, 2008
Publication date	Jul 28, 2020
Grant date	Jul 28, 2020

Abstract

The invention relates to compounds of formula I:

where a, R 1 , and R 3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

First claim

What is claimed is:

1. A pharmaceutical composition in unit dosage form comprising 1 mg to 20 mg of a compound of the formula:

or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises about 1 mg to about 15 mg of the compound or a pharmaceutically acceptable salt thereof.

3. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises 5 mg to 20 mg of the compound or a pharmaceutically acceptable salt thereof.

4. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises 7.5 mg to 15 mg of the compound or a pharmaceutically acceptable salt thereof.

5. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises 1 mg to 10 mg of the compound or a pharmaceutically acceptable salt thereof.

6. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises 10 mg of the compound or a pharmaceutically acceptable salt thereof.

7. The pharmaceutical composition of any one of claims 1 to 6 , wherein the pharmaceutical composition is a solid dosage form.

8. The pharmaceutical composition of any one of claims 1 to 6 , wherein the pharmaceutical composition is in the form of a capsule, tablet or pill.

9. The pharmaceutical composition of any one of claims 1 to 6 , wherein the pharmaceutical composition is in the form of a tablet.

10. A pharmaceutical composition in unit dosage form comprising 1 mg to 20 mg of a hydrochloride salt of a compound of the formula:

and a pharmaceutically acceptable carrier.

11. The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition comprises 1 mg to 15 mg of the hydrochloride salt of the compound.

12. The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition comprises 5 mg to 20 mg of the hydrochloride salt of the compound.

13. The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition comprises 7.5 mg to 15 mg of the hydrochloride salt of the compound.

14. The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition comprises 1 mg to 10 mg of the hydrochloride salt of the compound.

15. The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition comprises 10 mg of the hydrochloride salt of the compound.

16. The pharmaceutical composition of any one of claims 10 to 15 , wherein the pharmaceutical composition is a solid dosage form.

17. The pharmaceutical composition of any one of claims 10 to 15 , wherein the pharmaceutical composition is in the form of a capsule, tablet or pill.

18. The pharmaceutical composition of any one of claims 10 to 15 , wherein the pharmaceutical composition is in the form of a tablet.

Assignees

• Theravance Biopharma R&D Ip Llc

Inventors

• Patterson Lori Jean
• Stangeland Eric L

Classifications

• A61K31/451

  having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• C07D211/22 Primary

  by oxygen atoms · CPC title

• C07D211/32

  by oxygen atoms · CPC title

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title